7435. Pimozide

Nomenclature

CAS number: 2062-78-4
1-[1-[4,4-Bis(4-fluorophenyl)butyl]-4-piperidinyl]-1,3-dihydro-2H-benzimidazol-2-one; 1-[1-[4,4-bis(p-fluorophenyl)butyl]-4-piperidyl]-2-benzimidazolinone; 1-[4,4-di-(4-fluorophenyl)butyl]-4-(2-oxo-1-benzimidazolinyl)piperidine; R-6238; Orap (Janssen); Opiran (Cassenne).
C28H29F2N3O; mol wt 461.55.
C 72.86%, H 6.33%, F 8.23%, N 9.10%, O 3.47%.

Description and references

Prepn: Janssen, FR M3695 (1965 to Janssen), C.A. 66, 115709t (1967). Pharmacological studies: Janssen et al., Arzneim.-Forsch. 18, 261, 279, 282 (1968). Metabolism in rats: Soudijn, Wijngaarden, Life Sci. 8, 291 (1969). Clinical experience: Poldinger, Curr. Ther. Res. 13, 23 (1971). Pimozide blocks establishment but not expression of amphetamine-produced environment-specific conditioning: R. J. Beninger, B. L. Hahn, Science 220, 1304 (1983). Use in treatment of acute schizophrenia: B. Shopsin, G. Selzer, Curr. Ther. Res. 21, 755 (1977); in treatment of chronic schizophrenia: F. Kline et al., ibid. 768. In management of Gilles de la Tourette's syndrome: M. S. Ross, H. Moldofsky, Lancet 1, 103 (1977); A. K. Shapiro, E. Shapiro, Am. J. Psychiatry 140, 1235 (1983); eidem, J. Am. Acad. Child Psychiatry 23, 161 (1984).

Chemical structure

Properties

Microcrystals, mp 214-218°. Weak base, pKa 7.32. Almost insol in water (<0.01 mg/ml). Very slightly sol in dil aq solns of organic and mineral acids (<5 mg/ml).

Therapeutic Category

Antipsychotic.

Keywords

Antidyskinetic; Antipsychotic